Krystal Biotech Inc
Company Profile
Business description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Contact
2100 Wharton Street
Suite 701
PittsburghPA15203
USAT: +1 412 586-5830
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
275
Stocks News & Analysis
stocks
National Australia Bank earnings: Standing ground in business lending, but no earnings growth
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,950.18 | 14.59 | -0.18% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 74.80 | 0.16% |
| FTSE 100 | 9,682.57 | 53.21 | -0.55% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 23,004.54 | 49.46 | -0.21% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |